Immune-checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients
Downloads
Lung cancer is the primary cause of mortality in the world. It is able to manipulate the host immune response system through many mechanisms, such as through alteration of cytokines structure, forming regulator T-cells, obstruction of cellular immunity function, and the interference of tumor antigen presenting process. The new therapy approachment is produced by stimulating anti-cancer immune response, therefore the growth of lung cancer is able to inhibit. Immune checkpoint inhibition is considered as therapy for non-small cell lung carcinoma (NSCLC) after the unsuccesful treatment by platinum-based chemotherapy. Recent study shows that immune checkpoint inhibition monotherapy is more distinguished as first line therapy than platinum-based chemotherapy. Nonetheless, the effect of immunotherapy is only available for small population (30%) which has more than 50% PD-L1 programmed by the tumor. Therefore, some strategies are investigated to solve this issue. Nowadays, immunotherapy is expected to overcome lung cancer which is still being investigated in many studies.
Chen YM. Immune Checkpoint Inhibitors for Nonsmall Cell Lung Cancer Treatment. Journal of the Chinese Medical Association : JCMA. 2017; 80: 7-14.
Institute NC. Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version. 2017.
Society AC. Key Statistics for Lung Cancer.
Tan WW. Non-Small Cell Lung Cancer (NSCLC). 2016.
Wulandari L. Immunotherapy for Non-Small Cell Lung Cancer. Pertemuan Ilmiah Respirasi Surabaya, 2017.
Remon J, Pardo N, Martinez-Marti A, et al. Immune-Checkpoint Inhibition in First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients: Current Status and Future Approaches. Lung Cancer (Amsterdam, Netherlands). 2017; 106: 70-5.
Aguiar PN, Jr., De Mello RA, Barreto CMN, et al. Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: Emerging Sequencing for New Treatment Targets. ESMO Open. 2017; 2: E000200.
Soegiarto G. Immunology of Lung Cancer Pertemuan Ilmiah Respirasi Surabaya, 2017.
Pollard KM and Kono DH. Requirements for Innate Immune Pathways in Environmentally Induced Autoimmunity. BMC Medicine. 2013; 11: 100.
Ribas A. Tumor Immunotherapy Directed At PD-1. The New England Journal of Medicine. 2012; 366: 2517-9.
Rafei H, El-Bahesh E, Finianos A, Nassereddine S and Tabbara I. Immune-Based Therapies for Non-Small Cell Lung Cancer. Anticancer Research. 2017; 37: 377-87.
Network NCC. Non-Small Cell Lung Cancer Version 2.2018. 2017.
Naidoo J, Page DB, Li BT, et al. Toxicities of the Anti-PD-1 and Anti-PD-L1 Immune Checkpoint Antibodies. Annals of Oncology : Official Journal of the European Society for Medical Oncology. 2015; 26: 2375-91.
Wati F. Monitoring and Managing Immune-Related Advers Events in Lung Cancer. Pertemuan Ilmiah Respirasi Surabaya, 2017.
Society AC. How Immunotherapy is Used to Treat Cancer. American Cancer Society, 2015.
Haanen J, Carbonnel F, Robert C, et al. Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology : Official Journal of the European Society for Medical Oncology. 2017; 28: Iv119-Iv42.
Merrill SP, Reynolds P, Kalra A, Biehl J, Vandivier RW and Mueller SW. Early Administration of Infliximab for Severe Ipilimumab-Related Diarrhea in a Critically Ill Patient. The Annals of Pharmacotherapy. 2014; 48: 806-10.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (